Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

iPad

- PMLiVE

Double win for J&J’s schizophrenia franchise

Pharma company wins appeal against $1.2bn fine and Risperdal follow-up proves itself in trial

- PMLiVE

Abilify Maintena launches in Europe

Schizophrenia treatment is a key product to help Lundbeck replace lost Cipralex sales

Teva Pharma logo

Teva launches first inhaled antipsychotic in US

Adasuve available for the treatment of agitation associated with schizophrenia or bipolar disorder

- PMLiVE

Otsuka/Lundbeck say brexpiprazole works in phase III trial

On course as successor to antipsychotic Abilify

Roche Basel Switzerland

Setback for Roche as schizophrenia candidate fails studies

 Bitopertin misses primary endpoints in two phase III trials

- PMLiVE

FDA turns down Forest/Gedeon Richter’s antipsychotic

US regulator wants more information for cariprazine

What did the iPad ever do for us?

Tablets are here to stay, but capitalising on them requires moments of ‘wow’

iPad detailing: still room for pharma to improve

Doctors want to be 'wowed', and video is where iPads shine, says Manhattan Research

- PMLiVE

Vanda withdraws EU application for schizophrenia drug

CHMP had previously refused to back the approval of Fanaptum

- PMLiVE

Depot Abilify approval in US buoys Lundbeck and Otsuka

FDA licences the once-monthly version of Lundbeck's blockbuster schizophrenia drug

- PMLiVE

EU approves Alexza’s antipsychotic Adasuve

Company plans to launch it in third quarter of 2013 in partnership with Grupo Ferrer

Pharma’s 2012 … going mobile

This year patients, prescribers and the public increasingly turned to their mobile devices

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links